We review newly discovered monogenic immune-dysregulatory disorders that were reported in Pubmed over the last year.
INTRODUCTION
Over the last 20 years the discovery of monogenic defects that cause excessive activation of innate immune responses or adaptive/acquired immune dysregulation that leads to a break in immune tolerance have not only shaped our concepts of 'autoinflammation' and 'autoimmunity' but revealed targets for therapeutic intervention.
Many currently described monogenic 'autoinflammatory conditions' that present with sterile fever, neutrophilic skin rashes, and organ-specific inflammation are caused by gain-of-function mutations in innate immune sensors or by loss-offunction mutations in other molecules that can lead to 'intracellular stress'. In both instances, an IL-1 cytokine amplification loop is triggered and many diseases can successfully be treated with IL-1 inhibiting drugs [1 & ]. Recent discoveries described in this review challenge the IL-1-centered view of autoinflammation and suggest abnormal chronic production of Type I interferons as cause for a novel group of predominantly autoinflammatory diseases. Another group of diseases is caused by molecular defects that lead to abnormal cell differentiation, and mitochondrial or Golgi transport dysfunction that cause complex clinical phenotypes presenting with systemic and organ-specific inflammation. The molecular triggers and the inflammatory mediators that lead to the inflammatory disease manifestations remain incompletely understood in the latter disorders. Novel insights into 'autoimmune diseases' have been gained from the discovery of mutated genes that lead to dysregulation of T and B-cell function, with or without a loss of regulatory T-cell function and ultimately a break in central or peripheral T or Bcell tolerance.
The diseases described in this chapter expand the clinical disease spectrum of monogenic autoinflammatory and autoimmune conditions and illustrate molecular mechanisms that provide explanations for the considerable overlap between clinical features of innate and adaptive immune dysregulation. We have grouped the novel diseases into those that are predominantly leading to innate immune dysregulation (autoinflammation) and those that primarily cause acquired immune dysregulation (autoimmunity). Table 1 summarizes the newly recognized Mendelian diseases described in the past 12 months.
DISORDERS AFFECTING PREDOMINANTLY THE INNATE IMMUNE SYSTEM
Four immune-dysregulatory diseases described over the past 12 months are caused by gain-of function mutations in cytosolic innate immune sensors or their adaptor molecules. Three of these newly discovered conditions link autoinflammatory phenotypes to innate immune dysregulation of predominatly Type I IFN production and suggest a potent role of Type I IFNs in coordinating innate and adaptive immune responses in these conditions. One of the four diseases is associated with macrophage activation syndrome (MAS).
Stimulator of interferon genes-associated vasculopathy with onset in infancy
STING-associated vasculopathy with onset in infancy (SAVI) is an ultrarare autoinflammatory disease caused by de-novo gain-of-function mutations in TMEM173, which encodes the stimulator of interferon (IFN) genes (STING), an adaptor protein in the cytosolic DNA-sensing pathway 
Aicardi-Goutiè res syndrome 7
Aicardi-Goutières syndrome (AGS) is a rare disease caused by autosomal recessive mutations in the exonuclease TREX1; the ribonucleases RNASEH2A, RNASEH2B, and RNASEH2C; an enzyme with phosphohydrolase and nuclease activity, SAMHD1; and the double-stranded-RNA-specific adenosine deaminase ADAR1 [8] . In addition, autosomal-dominant mutations in IFIH1, encoding MDA5, are responsible
KEY POINTS
The monogenic immune-dysregulatory diseases can be caused by defects in molecules involved in either the innate or the adaptive immune reponses.
In general, innate immune system dysregulation leads to 'autoinflammatory' diseases phenotypes and adaptive immune system dysregulation leads to primary immunodeficiencies with lymphoproliferation with or without autoimmunity.
An overlap of clinical and immunological phenotypes is increasingly observed in both groups of immunedysregulatory diseases.
The study of Mendelian immune-dysregulatory disease mechanisms can provide insights into novel inflammatory disease pathways and lead to the discovery of novel therapeutic targets. ] and variable immune manifestations, including rashes, thrombocytopenia and arthritis [10] . Four of 11 reported patients had neonatal disease-onset, five patients developed disease between 6 and 24 months of age, and two mutation-positive carriers remained asymptomatic into adulthood [9 && ]. Symptomatic patients had severe developmental delay. In-vitro assays showed that disease-causing IFIH1 mutations enhance double-stranded RNA binding and baseline or ligand-induced IFN signaling [9 && ]. Interestingly, one of the AGS7 mutations (p.R779H) was found in a patient with 'early-onset juvenile systemic lupus erythematosus', who presented with arthritis, livedo reticularis, necrotizing cutaneous vasculitis, antiphospholipid syndrome, high-positive anti dsDNA antibody titers, lower limb spasticity and selective IgA deficiency [11] .
Atypical Singleton-Merten syndrome (atypical SMS)
Mutations in DDX58 encoding RIG-I have recently been described in 11 patients from two families with glaucoma and skeletal abnormalities [12 & ]. The musculoskeletal manifestations include arthritis of hands and feet, joint contractures, calcific tendinitis and erosive changes in the terminal tufts of the distal phalanges. Four patients had aortic and valvular calcification; psoriasiform rashes were present in eight individuals and most patients had glaucoma [12 & ]. Transfection of wildtype and mutant DDX58 into HEK293T cells showed increased basal reporter gene activity of NF-kB and of the IFNB1 enhancer region PRDIII-I [12 & ]. An increased expression of IFNB1 and ISG15 in mutant compared with WTconstruct transfected cells was further enhanced by polyI:C stimulation [12 & ]. Additionally, constitutive IRF3 phosphorylation and dimerization were induced by high amounts of mutant DDX58 [12 & ]. Gain-of-function mutations in the innate immune sensor NLRC4, which assembles a caspase-1 activating inflammasome, cause a novel autoinflammatory syndrome and predispose to macrophage-activation syndrome.
NLRC4-related macrophage-activation syndrome/syndrome of enterocolitis and autoinflammation associated with mutation in NLRC4
Activating heterozygous gain-of-function mutations in the innate immune sensor NLRC4, which assembles a caspase-1 activating inflammasome, ]. NLRC4-associated MAS has been named syndrome of enterocolitis and autoinflammation associated with mutation in NLRC4. Another NLRC4 mutation (p.H443P) resulted in a familial cold autoinflammatory syndrome-like phenotype in 13 members from a large Japanese kindred [15 & ] who presented with cold-induced fever episodes, urticaria-like rashes and arthralgia starting between 2 and 3 months of age. Transfection assays demonstrated that the disease-causing mutations increase NLRC4 oligomerization and cleavage of procaspase-1 that result in secretion of IL-1b [ ].
Loss-of-function mutations in intracellular enzymes or transport proteins can generate intracellular stress and inflammatory diseases, although the molecular mechanisms that lead to the inflammatory disease manifestations remain elusive. The presentation of these diseases is often with clinical features of innate and adaptive immune dysregulation.
Deficiency of adenosine deaminase 2
Autosomal recessive mutations in CECR1, encoding the enzyme adenosine deaminase 2 (ADA2), cause an early-onset vasculopathy resembling polyarteritis nodosa [ 
].
Gene-expression studies showed a marked upregulation of neutrophil-expressed genes, suggesting a potential pathogenic role for activated neutrophils [20] . Therapeutic interventions include anti-TNF agents, fresh-frozen plasma, recombinant ADA2, and hematopoietic stem cell transplantation (HSCT) [ ]. Occult multiorgan failure and/or cardiomyopathy were seen in seven patients; early allogenic bone marrow transplant was curative in one patient [22 & ]. TRNT1 encodes an enzyme that adds two cytosine-and one adenosine-(CCA) residues to the 3' end mitochondrial and cytosolic tRNA molecules, which is necessary for tRNA aminoacylation [23] . The disease-causing mutations lead to a reduction in CCA enzyme activity, defective mitochondrial translation, and the inability to detect tRNAs with backbone damage [24] . This defect is thought to result in a 'loss of quality-control-mechanisms' that recognize and prevent damaged tRNA from CCA maturation and from entering the ribosome machinery of protein synthesis, thus suggesting a role of CCA addition in intracellular stress responses [25] . ]. Most patients had autoantibodies, such as antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies (ANCA), and rheumatoid factor (RF). Functional assessment of patient-derived cells and in-vitro assays showed evidence of increased endoplasmic reticulum stress and enhanced production of cytokines that promote the expansion of Th17 cells (IL-23 p19, IL-12 p40, IL-12 p35, IL-1b, and IL-6) [26 && ]. Similarities in lung phenotype of COPA-associated disease and SAVI patients may suggest dysregulation in Type I IFN production. In COPA-associated disease, most examined clinical features suggest a predominance of adaptive immune dysregulation.
Interstitial lung disease and arthritis caused by COPA mutations
In some of the diseases described in the last year, the mechanisms leading to the inflammatory manifestations remain elusive.
AP1S3-associated pustular psoriasis
Fifteen unrelated patients with either generalized pustular psoriasis or palmar plantar pustulosis had heterozygous mutations in the AP1S3 gene, which encodes the s1C subunit of the cytosolic transport complex AP1 [27 & ]. Disease-causing mutations (p.F4C and p.R33W) were predicted to destabilize the 3D structure of the AP-1 complex [27 & ]. AP1S3 silencing resulted in disrupted endosomal translocation of TLR3 and in a marked inhibition of its canonical downstream signaling [27 & ].
TNF-receptor-associated periodic syndrome because of mutations in TNFRSF11A
Recurrent, long-lasting attacks presenting with fever, abdominal pain, lymphadenopathy, and macular rashes were described in three patients from two families with heterozygous mutations in TNFRSF11A, the gene-encoding receptor activator of NF-kB (RANK) [28] . One patient had a 10 Mb genomic duplication of 30 genes followed by a 9.5 Mb deletion containing 29 genes that included TNFRSF11A [28] . The complex phenotype, including congenital heart disease, cleft palate, facial dysmorphism, and mental retardation [28] , is likely caused by gene duplication or the deletion of other genes in the 29-gene-deletion cluster. Screening for TNFRSF11A mutations in 127 patients with similar inflammatory manifestations identified a frameshift deletion in TNFRSF11A (p.M416Cfs Ã 110) 110) in an adolescent and her mother who presented with later-onset (10 and 18 years of age) fever attacks as above, but also had erythema nodosum, anterior uveitis, headaches, elevated CRP, and hypergammaglobulinemia [28] . Due to the clinical similarities with TNF receptor-associated periodic syndrome (TRAPS), this disease has been named TRAPS11.
Monogenic systemic juvenile idiopathic arthritis caused a mutation in LACC1
A homozygous mutation in a conserved cysteine residue at position 284 (p.C284R) in LACC1, which encodes the enzyme laccase (multicopper oxidoreductase) domain-containing 1, causes an inflammatory disease that clinically fulfills criteria for systemic juvenile idiopathic arthritis (JIA) in 13 patients from five Saudi Arabian consanguineous families [29 & ]. All patients presented with characteristic fever, erythematous maculopapular rashes, chronic polyarthritis, leukocytosis, thrombocytosis, and elevated markers of inflammation [29 & ]. None of the patients had MAS. All patients presented with moderate to severe disease, and were unresponsive to treatment with NSAIDs, systemic corticosteroids, methotrexate, and biological agents, including anti-TNF (all 13 patients) anti-IL-6 (five patients) or rituximab (three patients) [29 & ]. Three novel monogenic defects that lead to constitutive T-cell activation affect T and B-cell homeostasis. An impaired regulatory T (T reg) cell function is observed in two of the three diseases listed below.
DISORDERS AFFECTING PREDOMINANTLY THE ACQUIRED/ ADAPTIVE IMMUNE SYSTEM

STAT3 gain-of-function mediated early-onset lymphoproliferation and autoimmunity
Germline-dominant-negative/loss-of-function mutations in STAT3 cause hyper-IgE syndrome with recurrent infections [30, 31] . Recently, activating (gain-of-function) STAT3 mutations were found in an early-onset multiorgan autoimmune disease with lymphoproliferation [32 && ]. Four mutations were identified in five patients, who presented with type1 diabetes mellitus, autoimmune enteropathy, autoimmune thyroiditis, ILD, and features of systemic JIA [32 && ]. Other manifestations were short stature, eczema, and dental anomalies [32 && ]. An additional study [33 && ] expanded the phenotype of the disease and other clinical manifestations were autoimmune cytopenias (hemolytic anemia, neutropenia, and/or thrombocytopenia), hepatitis, atopic dermatitis, alopecia, and scleroderma. Most of these patients (8 out of 13) had recurrent and/or severe infections [33 && ]. In both studies [32 && ,33 && ], increased STAT3 transcriptional activity and a diminished T reg function were observed.
CTLA-4 haploinsufficiency with autoimmune infiltration
In two patient cohorts, heterozygous loss-of-function mutations in the inhibitory receptor, CTLA4 that is expressed on activated T-and T reg cells cause a complex immune-dysregulatory phenotype [ 
Immunodeficiency with lymphoproliferation caused by a dominant activating mutation in PIK3R1
Gain-of-function mutations in PIK3CD, encoding the p110d catalytic subunit of phosphatidylinositol 3-kinase (PI3K), were described to cause an immunedysregulatory disease with autoimmune manifestations and immunodeficiency named PASLI [36] or APDS [37] . More recently, four patients from three families with a similar phenotype had a splice site mutation in another gene in the same pathway, PIK3R1, encoding the regulatory protein of PI3K pathway, p85a [38 & ]. Patients present with recurrent sinopulmonary infections and diffuse lymphadenopathy. Three of four patients had splenomegaly (two had a splenectomy), and two developed bronchiectasis. Other manifestations included inflammatory bowel disease, autoimmune thrombocytopenia and arthritis, and severe JIA like disease [38 A central immune tolerance defect similar to autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome is observed in the disease below.
Immune-dysregulatory disease caused by PRKDC mutations
Variable disease expression is seen in patients with mutations in PRKDC, encoding a catalytic subunit of DNA-dependent protein kinase (DNA-PK), a double-stranded DNA break repair enzyme [40, 41] . Enzymatic activity can vary in patients with the same mutation (p.L3062R). Patients with complete absence of DNA-PK enzymatic activity present with T -B -NK þ SCID [40, 41] . Patients with residual enzymatic activity present with autoimmune features, positive ANA, granulomas in skin and spleen, arthritis and recurrent lung infections with bronchiectasis [42 & ]. Two reported patients had increased numbers of inflammatory CD4þCD16þ monocytes, and severely reduced CD4þT, CD8þT, and T reg cells [42 & ]. Mutant DNA-PK impairs the ability of the autoimmune regulator to regulate ectopic expression of tissue-specific antigens in medullary thymic epithelial cells [42 & ], thus suggesting a critical role of PRKDC in impaired negative selection of autoreactive T cells [43] .
CONCLUSION
The recently discovered monogenic immune-dysregulatory diseases have substantially widened our understanding of pathogenic pathways that cause predominantly innate or adaptive immune response dysregulation.
The discovery of mutations in viral innate immune sensor pathways coupled to chronically increased IFN production introduces Type I IFNs as key cytokines in causing a novel group of autoinflammatory diseases, as potent activators of innate and adaptive immune responses [44] . Future studies on the release of Type I IFNs will assist in dissecting the contribution of innate and adaptive immune dysregulation in these conditions. Novel disorders caused by mutations in molecules associated with cell differentiation, mitochondrial, and Golgi transport provide opportunities to study pathways that cause various forms of cellular stress and their link to proinflammatory pathways. Genetic defects that lead to novel monogenic autoimmune diseases provide insights into pathways that lead to a break in T and B-cell tolerance.
Taken together, the study of early-onset immunedysregulatory conditions continues to provide an opportunity to discover and understand the novel molecular pathways that lead to tissue-specific inflammation and provide novel targets to explore treatment for patients with rare syndomes who present wth excessive inflammation but also for patients with more common inflammatory disorders.
